Multiple myeloma—intermittent, combination chemotherapy compared to continuous therapy

Abstract

Controversy exists regarding the efficacy of various treatment schedules and drug combinations for patients with multiple myeloma. Fifty‐three patients with this malignancy were evaluated. In a prospective program, 31 patients received an intermittent combination drug schedule using melphalan and prednisone, and the results were compared to a group of 22 patients, studied retrospectively, who had been treated with continuous cyclophosphamide or melphalan administered to hematologic tolerance. Objective response occurred in 74% of those receiving the intermittent combination regimen compared to a 41% response rate for those receiving continuous alkylating agents. Eight patients who relapsed while on continuous alkylators were switched to the intermittent combination regimen, and three responded. Morbidity was not increased with intermittent combination drug program. Copyright © 1972 American Cancer Society